Independent research and development (R&D) is the foundation of innovation. With the deepening of global economy integration, R&D globalization has been accomplished in foreign companies. The global resources have been involved in the discovery, new research and development of new drugs. Compared with foreign counterparts, the weak innovation foundation, the lag behind mechanism of industrialization of scientific and technological achievements, the fund shortage and other congenital deficiency still exist in Chinese enterprises. China's small and medium-sized enterprises cannot input the limited funds focus into R&D field. However, after long-term development, some domestic outstanding enterprises already have the abundant fund and R&D strength, which can challenge the dominant position of foreign companies in the world. In the long run, if we want to revitalize the Chinese medicine industry, the investment of R&D field must be increased, the transition from the generics towards creating must be realized, and finally the strength of the international competition will be qualified. Through medical alliance, the scale of enterprises can be expanded and the economy of scale can be realized. At the same time, the pharmaceutical R&D alliances also can help to realize the resources sharing. On the basis of Resource Theory in the explanation of alliance formed, the company takes advantage of alliance to optimize the allocation of resources, to maximize the value of resources. Sustainable different kinds of complementary resources, is not only the competitive advantages of enterprises, as well as the source of strategic alliance. In recent years, people always focus on the theoretical model and strategy research in the development of pharmaceutical R&D alliance. However, there is a lack of study and analysis on the resources interchange field in the pharmaceutical R&D alliance. Based on the literature review and related information analysis of Chinese pharmaceutical R&D alliance, the development in recent ten years of pharmaceutical R&D alliances in China were summarizes in the present paper. Second-hand data collection, interview, questionnaire and other methods were used in our investigationIn order to find the link point and analyze the influence factors of the exchange of resources in R&D alliances, the requirement and advantages of resources of the pharmaceutical R&D industry including the CRO enterprises, pharmaceutical enterprise and national R&D institutions were investigated. Following the analysis mentioned above, we suggested that industries, universities and research institutes should be integrated together for the R&D of new drugs. Meanwhile, according to the platform building of R&D alliances, we also suggested that enterprise, research institutions and government should be cooperated harmoniously to promote the transfer from scientific and technological achievements into reality, and to promote the marketization of productive R&D alliance. Key words: Pharmaceutical industry; CRO; R&D alliance; Medicine

自主研發是創新的基礎，隨著全球經濟一體化的深入，國外公司的研發都已 經做到了全球化，利用全球的資源進行新藥發掘、研究和開發。與國外同行相比， 中國企業存在創新基礎薄弱、科技成果產業化的機制落後、資金投入不足等先天 不足的問題。中國的中小企業不能將其有限的資金投入重點投入到研發領域。但 是，我們少數國內優秀企業通過積累，已經具備雄厚的資金和研發實力，可以與 國外企業一拼高下。從長遠來看，要振興我國的醫藥產業，必須加大科研投入， 從仿製逐步走向創制，使其具有與國際競爭的實力。 通過醫藥聯盟能幫助企業做大規模，實現規模經濟；通過醫藥研發聯盟可以 實現優勢資源分享。在形成戰略聯盟的資源理論中提出，戰略實體利用聯盟來優 化資源配置，使資源的價值達到最大化。可持續的不同種類的互補資源，不僅是 企業競爭優勢的來源，也是企業建立戰略聯盟的原因。近些年對中國醫藥行業的 研發（R&D）聯盟研究多集中於理論模型和策略研究，而對醫藥研發聯盟中資 源交換的因素的分析研究較少。 本文通過對中國醫藥行業 R&D 聯盟回顧性文獻綜述和相關資訊整理分析， 總結了醫藥 R&D 研發聯盟近十年在中國的發展狀況，利用二手資料收集、訪談、 問卷等方法，對醫藥研發產業中的三個組成部分：CRO 企業、制藥企業和國家 研發機構進行資源優勢和資源需求的考察，找出其研發聯盟資源交換的切合點， 並分析影響資源交換的因素。提出“產、學、研”三結合研發新藥的新的聯盟政策 建議。最後以澳門出發，根據研究結果，針對澳門與廣東省的醫藥研發資源優勢， 搭建粵澳研發聯盟平臺，以政府與企業、研究機構合作協調，促進科技成果向現 實生產力轉化，促進 R&D 聯盟市場化的分析建議。 關鍵字：研發聯盟、CRO、制藥企業、醫藥